Why the study?
Does targeted NOAC administration guided by continuous rhythm assessment with an insertable cardiac monitor reduce time on anticoagulation in patients with nonpermanent AF?
Population
59 patients on NOAC with nonpermanent AF and CHADS2 score 1 or 2, 75% male, mean age 67 ± 8 years, 76%…
Design
Cohort
Follow-up
mean 466 ± 131 days
Key result
A targeted strategy of ICM-guided intermittent NOAC administration resulted in a 94% reduction in time on NOAC compared to chronic anticoagulation, with no strokes or deaths over 466 days.
Authors
Loading...
May reduce anticoagulation exposure in nonpermanent AF; hypothesis-generating and leaves open need for randomized safety confirmation.
Observational (n=59)
Yes
Does targeted NOAC administration guided by continuous rhythm assessment with an insertable cardiac monitor reduce time on anticoagulation in patients with nonpermanent AF?
A targeted strategy of ICM-guided intermittent NOAC administration is feasible and significantly reduces time on anticoagulation in patients with nonpermanent AF.
Passman et al. (2015) conducted an observational in Atrial Fibrillation (n=59). Targeted anticoagulation guided by continuous rhythm assessment with an insertable cardiac monitor vs. Chronic anticoagulation (historical) was evaluated on Time on NOAC, stroke, and bleeding. A targeted strategy of ICM-guided intermittent NOAC administration resulted in a 94% reduction in time on NOAC compared to chronic anticoagulation, with no strokes or deaths over 466 days.